CHMP recommends refusal of market authorisation for tagraxofusp (Elzonris) for blastic plasmacytoid dendritic cell neoplasm

Tagraxofusp, diphtheria toxin, linked to interleukin-3 to target treatment to cancer cells, could not be approved for this use as the CHMP was concerned that due to the design of the study and the small number of patients involved.


European Medicines Agency